EHA26: AstraZeneca battles Roche in untreated follicular lymphoma

AstraZeneca’s SOUNDTRACK-F1 study aims to improve on related risks seen with chemotherapy-including treatments in follicular lymphoma. AstraZeneca’s SOUNDTRACK-F1 study aims to improve on related risks seen with chemotherapy-including treatments in follicular lymphoma. The outcome of the contest between AstraZeneca’s surovatamig and Roche’s Lunsumio will be as exciting to follow in the next few years as it is significant to patients with advanced follicular lymphoma. Image credit: [Andrii Spy_k]/Shutterstock.com At the 2026 European Hematological Association (EHA) conference, held in Stockholm on 11–14 June, AstraZeneca shared preliminary safety data from its Phase III trial SOUNDTRACK-F1 (NCT06549595). This explores its pipeline agent surovatamig,…

Source: Clinical Trials Arena